iVascular, a Barcelona, Spain-based catheter maker, won CE Mark for its new microcatheter called Navitian. The microcatheter can be used to facilitate, guide and support a guidewire while accessing the coronary system, the exchange of guidewire and injection of radiopaque contrast media or saline solutions.
Navitian was specifically designed to achieve a desirable navigation in cases of CTO (chronical total occlusions).
It stands out for its superior crossability and exceptional penetration capacity due to the internal and external conical transition. Other key features of Navitian include:
“At iVascular we work continuously for the improvement of today’s therapies, to achieve the best benefit for the patient,” said Lluis Duocastella, CEO of iVascular S.L.U.
The device was developed to help address chronic total occlusions, which are especially difficult to treat. With the braided design, the catheter maintains strength while being pushed through tortuous anatomy and during penetration of occlusions, reports MedGadget.
Founded in 2010 in Barcelona, Spain, iVascular is a fast-growing company with an aim of developing advanced medical devices and therapies for the treatment of disorders of the cardiovascular system. The team that started iVascular owns more than 20 years of experience in the field of cardiovascular devices, being responsible of achieving one of the first CE marks for a drug eluting stent more than 12 years ago.
iVascular is an international project, founded by 5 industrial companies based in Spain and Canada with focus in chemical engineering, pharmacy, metallurgy and medical devices. All together they support iVascular with more than 2.100 employees, 1.150 million euros of revenue and potential presence in more than 100 countries.
Read more Omron and physIQ Collaborate to Improve Cardiovascular Patient Care
The company is commercially active in more than 66 countries including Spain, Portugal, France, Germany, UK, Italy, Belgium, Brazil, Canada, Russia, Turkey, Egypt, Saudi Arabia, UAE and others.
